Company overview
Alltrna develops universal tRNA medicines to restore disrupted protein production by reading through premature termination codons, targeting thousands of rare and common diseases with shared genetic mutations. The company's AI/ML-powered platform designs, engineers, synthesizes, and delivers chemically modified tRNA oligonucleotides with enhanced potency and activity. Founded in 2018 by Flagship Pioneering, Alltrna pioneers tRNA therapeutics to modulate protein expression and treat genetic disorders.
Alltrna is listed in the NovaPharmaNews Supplier Hub as a Life Science Reagents partner serving United States & Americas. Core focus areas include trna medicines, genetic disease therapeutics, premature stop codon, ai/ml drug discovery, protein restoration platform.
Industry categories: Life Science Reagents. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.alltrna.com
- Categories
- Life Science Reagents
- Markets served
- United States & Americas
- Keywords
- trna medicines, genetic disease therapeutics, premature stop codon, ai/ml drug discovery, protein restoration platform
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What is Alltrna's core technology platform?
- Alltrna's platform uses proprietary AI/ML tools and internal expertise to design, modify, synthesize, and deliver chemically modified tRNA oligonucleotides that read through premature stop codons and restore full-length protein production.
- What diseases does Alltrna target?
- Alltrna targets thousands of rare and common diseases caused by premature termination codons or nonsense mutations, enabling a unified tRNA medicine approach regardless of the specific gene affected.
- What is the development stage of Alltrna's tRNA medicines?
- Alltrna has validated its platform with in vivo demonstrations of tRNA readthrough for common premature stop codons and pioneered chemical synthesis processes for modified tRNAs, with a pipeline focused on Stop Codon Diseases.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
